Global Oncology | Specialty

The OncLive® Global Oncology condition center page is a comprehensive resource for clinical news and international expert insights on treatment of patients with cancer. This page features articles focused on ex-US regulatory news, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing global research in oncology care.

Retesting for HER2 Upon Breast Cancer Relapse May Provide New Therapeutic Opportunities

May 8th 2021

Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse.

Shorter Duration of Adjuvant Trastuzumab Shows Long-Term Survival Benefit in Select HER2+ Early Breast Cancer

May 8th 2021

Although administering trastuzumab for 1 year in patients with HER2-positive early breast cancer continues to be standard, a 9-week de-escalation approach may be a reasonable option in a large proportion of the real-world HER2-positive population.

Ribociclib/Endocrine Therapy Improves OS Regardless of Age in Advanced HR+/HER2- Breast Cancer

May 7th 2021

Ribociclib plus endocrine therapy improved overall survival and post-progression outcomes in pre- or postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer irrespective of age.

Atezolizumab Plus Carboplatin Induces Early Efficacy Signals in Invasive Lobular Breast Cancer

May 7th 2021

Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression, according to initial findings of the non-randomized phase 2 GELATO trial.

Breast Cancer Survivors Need More Tailored Follow-Up Care

May 7th 2021

Post-treatment care for breast cancer survivors must be personalized to address each survivor’s unique experiences.

Frontline Atezolizumab Approved in Europe for PD-L1–High Metastatic NSCLC

May 5th 2021

The European Commission has approved atezolizumab for use as a frontline treatment in patients with metastatic non–small cell lung cancer whose tumors have a high PD-L1 expression and do not harbor EGFR or ALK aberrations.

Enzalutamide Approved in Europe for Metastatic Hormone-Sensitive Prostate Cancer

May 4th 2021

The European Commission has approved enzalutamide for the treatment of adult patients with metastatic hormone-sensitive prostate cancer.

Risk-Adapted Therapy Feasible in Newly Diagnosed Ultra High–Risk Myeloma

April 28th 2021

Centrally stratified risk-adapted clinical trials in patients with newly diagnosed multiple myeloma were shown to be feasible, addressing an unmet need and providing the opportunity for rapid clinical development of novel therapies.

EU Panel Recommends Adjuvant Osimertinib in Early-Stage EGFR+ NSCLC

April 26th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended osimertinib for the adjuvant treatment of adult patients with stage IB, II, or IIIA EGFR-mutated non–small cell lung cancer following complete tumor resection with curative intent.

Bringing Individualized Care to Patients With Breast and Ovarian Cancers in the Caribbean

April 26th 2021

Current breast cancer screening practices in the Caribbean exclude the majority of the younger patient population, thereby leaving many cases of breast cancer undiagnosed.

EMA Validates Type II Variation Marketing Authorization Application for Selinexor Triplet in Multiple Myeloma

April 26th 2021

The European Medicines Agency has validated a Type II Variation Marketing Authorization Application to Karyopharm Therapeutics Inc. for selinexor in combination with bortezomib and low-dose dexamethasone as a treatment for adult patients with multiple myeloma who have received at least 1 prior therapy.

EU Panel Recommends Nivolumab/Ipilimumab in Frontline Unresectable Malignant Pleural Mesothelioma

April 23rd 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the combination of nivolumab and ipilimumab as a frontline treatment for adult patients with unresectable malignant pleural mesothelioma.

Oral Azacitidine Recommended for EU Approval in AML

April 23rd 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion for the approval of oral azacitidine as a maintenance treatment for adult patients with acute myeloid leukemia who had a complete remission or CR with incomplete blood count recovery after induction therapy with or without consolidation treatment, and who are ineligible for or choose to not undergo hematopoietic stem cell transplant

Venetoclax-Based Regimens Get European Nod for Newly Diagnosed, Chemo-Ineligible AML

April 23rd 2021

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended to approve venetoclax for use in combination with hypomethylating agents for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.

Dostarlimab Approved in Europe for Advanced dMMR Endometrial Cancer

April 23rd 2021

The European Commission has granted conditional marketing authorization to dostarlimab for the treatment of patients with microsatellite instability–high/mismatch repair deficient recurrent or advanced endometrial cancer who have progressed on or following prior therapy with a platinum-containing regimen.

Toripalimab/Chemo Combo Improves Survival in Frontline Esophageal Squamous Cell Carcinoma

April 22nd 2021

The frontline combination of toripalimab and cisplatin/paclitaxel reached its prespecified primary end points of progression-free and overall survival in patients with advanced esophageal squamous cell carcinoma in the phase 3 JUPITER-06 trial.

NICE Recommends Trastuzumab Deruxtecan in Advanced HER2+ Breast Cancer

April 20th 2021

The National Institute for Health and Care Excellence has published draft guidance that recommends fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive breast cancer following 2 or more anti-HER2 therapies.

Tocilizumab May Have Activity Against COVID-19–Associated Cytokine Storm in Myeloma

April 20th 2021

Tocilizumab may represent a potential treatment option with double action against cytokine storm due to COVID-19 in a subset of patients with active multiple myeloma and severe infection with the virus.

Subcutaneous Daratumumab Plus VCd Approved in Canada for Newly Diagnosed Light Chain Amyloidosis

April 19th 2021

Health Canada has approved daratumumab injection, a subcutaneous formulation of daratumumab, for use in combination with bortezomib, cyclophosphamide, and dexamethasone in the treatment of patients with newly diagnosed light chain amyloidosis.

Isatuximab Plus Carfilzomib/Dexamethasone Approved in Europe for Relapsed Myeloma

April 19th 2021

The European Commission has approved isatuximab for use in combination with carfilzomib and dexamethasone in the treatment of patients with relapsed multiple myeloma who have received at least 1 previous therapy.